Pfizer Enters Migraine Market With Biohaven Acquisition

Pfizer is forking over $11.6 billion to purchase migraine treatment maker Biohaven. It’s a bid by Pfizer to leverage its sales power to reap the benefits of what has become the hot-ticket pill in a new breed of drugs for migraines...